Tag: investigation

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving EchoStar Corporation (NASDAQ: SATS) focused on whether EchoStar and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of investors of fashion startup CaaStle, Inc. Our investigation concerns whether CaaStle has violated the federal securities laws and/or engaged in other unlawful business practices.

BALA CYNWYD, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Provident Bancorp, Inc. (“Provident” or the “Company”) (Nasdaq - PVBC) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to NB Bancorp, Inc. (“Needham”) (Nasdaq – NBBK). Under the terms of the stock and cash transaction, stockholders of Provident will receive for each share of Provident common stock, at the holder's election, either (i) 0.691 shares of Needham common stock or (ii) $13.00 in cash subject to allocation procedures.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. (“Caleres” or the “Company”) (NYSE: CAL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apple Inc. (“Apple” or the “Company”) (NASDAQ: AAPL).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi^® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI^® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.